title: Engineered in-situ depot-forming hydrogels for intratumoral drug delivery.
abstract: Chemotherapy is the traditional treatment for intermediate and late stage cancers. The search for treatment options with minimal side effects has been ongoing for several years. Drug delivery technologies that result in minimal or no side effects with improved ease of use for the patients are receiving increased attention. Polymer drug conjugates and nanoparticles can potentially offset the volume of drug distribution while enhancing the accumulation of the active drug in tumors thereby reducing side effects. Additionally, development of localized drug delivery platforms is being investigated as another key approach to target tumors with minimal or no toxicity. Development of in-situ depot-forming gel systems for intratumoral delivery of immuno-oncology actives can enhance drug bioavailability to the tumor site and reduce systemic toxicity. This field of drug delivery is critical to develop given the advent of immunotherapy and the availability of novel biological molecules for treating solid tumors. This article reviews the advances in the field of engineered in-situ gelling platforms as a practical tool for local delivery of active oncolytic agents to tumor sites.
authors.affiliation: Drug Delivery and Device Development, Medimmune LLC, United States.
authors.forename: Amir
authors.initials: A
authors.lastname: Fakhari
authors.affiliation: Drug Delivery and Device Development, Medimmune LLC, United States. Electronic address: subramonya@medimmune.com.
authors.forename: J
authors.initials: J
authors.lastname: Anand Subramony
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000378:metabolism; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D004339:Drug Compounding; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D020100:Hydrogels; D015552:Injections, Intralesional; D009369:Neoplasms / Q000235:genetics / Q000378:metabolism / Q000628:therapy* / Q000821:virology; D050130:Oncolytic Virotherapy / Q000379:methods*; D050504:Oncolytic Viruses / Q000235:genetics / Q000378:metabolism; D011108:Polymers / Q000737:chemistry*
chemical_list: D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D020100:Hydrogels; D011108:Polymers
keywords: Anticancer drug; Biologics sustained release; Engineered hydrogel; In-situ gelling; Intratumoral drug delivery